Healthcare
fromFortune
5 days agoNovo Nordisk wants to keep its crown leading the weight loss drugs pack-despite outlook downgrades and lawsuits, its CFO has a plan | Fortune
Novo Nordisk faces declining sales and stock after GLP-1 competition; success depends on launching new products like Wegovy pill, CagriSema, and amycretin.